1-7 of 7
Pau Montesinos Fernandez, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Peter Paschka, MD, Hervé Dombret, MD, Xavier Thomas, MD PhD, Christian Recher, MD PhD, Sylvain Chantepie, MD, Pau Montesinos Fernandez, MD PhD, Evelyn Acuña-Cruz, MD, Paresh Vyas, MRCP, FRCP, FRCPath, Karl-Anton Kreuzer, MD, Michael Heuser, Klaus H. Metzeler, MD, Michael Dennis, MD, Bruno Quesnel, MD PhD, Mathilde Hunault-Berger, MDPhD, Mohamad Mohty, MD PhD, Arnaud Pigneux, MD PhD, Stephane De Botton, Daniela Weber, MSc, Konstanze Döhner, Gary Milkovich, PharmD, John Reitan, PharmD, Sarah C MacDonald, SD, Deborah Casso, MPH, Michael Storm, MSc, Hua Liu, PhD, Stephanie M. Kapsalis, BS, Eyal C. Attar, MD, Thomas Winkler, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-136957
Published: 2020
Journal Articles

A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group

Fernando Ramos, David Martinez-Cuadron, Josefina Serrano, Maria Lopez-Pavia, Marta Fuertes-Nuñez, Teresa Bernal, Juan Ignacio Rodriguez-Gutierrez, Isabel Recio, Ana Garrido, Daniel Garcia, Claudia Lucia Sossa, MD, Cristina Gil, Rosario Varela, Pilar Martinez-Sanchez, Maria Angeles Foncillas, Mar Tormo, Antonia Cladera, Graca Esteves, José F. Falantes, Adolfo de la Fuente, Blanca Boluda, Miguel A. Sanz, Pau Montesinos Fernandez, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 648.
https://doi.org/10.1182/blood-2019-125053
Published: 2019
Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 643.
https://doi.org/10.1182/blood-2019-130362
Published: 2019
Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Rosa M. Ayala, MD PhD, Inmaculada Rapado, David Martínez-Cuadron, MD, Esther Onecha, PhD, Laura Rufian, Miss, Alexandra Juarez, Juan Bergua Burgues, Susana Vives, MD, Jesús Lorenzo Algarra, Mar Tormo, MD PhD, Pilar Martinez, MD, Josefina Serrano, Pilar Herrera, MD, Fernando Ramos, Olga Salamero, MD, Esperanza Lavilla, Cristina Gil, MD, Jose Luis Lopez Lorenzo, MD, Maria-Belen Vidriales, MD, Jorge Labrador, MD, José F. Falantes, Maria Jose Sayas, Bruno Paiva, PhD, Eva Barragán, Felipe Prosper, MD PhD, Miguel A. Sanz, Joaquin Martinez Lopez, MD PhD, Pau Montesinos Fernandez, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3891.
https://doi.org/10.1182/blood-2019-127187
Published: 2019
Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Josep-Maria Ribera, MD PhD, Olga García, Pilar Martinez, MD, Pau Montesinos Fernandez, MD PhD, Blanca Boluda, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, Susana Vives, MD, Mar Tormo, MD PhD, Jesús María Hernández-Rivas, MD PhD, Joaquin Martinez-Lopez, MD PhD, Ramón García-Sanz, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3874.
https://doi.org/10.1182/blood-2019-125558
Published: 2019
Journal Articles

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Josep-Maria Ribera, MD PhD, Olga García, Marta Cervera, MD, Carlos Rguez, Maialen Sirvent, Ferran Vall-Llovera, MD, Pau Abrisqueta, MD PhD, Josefina Serrano, Buenaventura Buendía, Pau Montesinos Fernandez, MD PhD, Susana Vives, MD, Juan Miguel Bergua Burgues, Mariana Beatriz Bastos-Oreiro, PhD MD, Evelyn Acuña, María José Moreno, MD, Irene García-Cadenas, Maria Jose Terol, Jesús María Hernández-Rivas, MD PhD, Antonio Garcia-Guiñon, MD, Pilar Herrera Puente, Santiago Mercadal, MD, Iulia Ivan, Antonia Cladera, Eva Gimeno Vázquez, Anna Torrent, Alfons Serrano-Maestro, MD, Cristina Barrenetxea, Daniel García, MD, Reyes Arranz, Ana Sebrango, Natalia Alonso, Daniel Martínez-Carballeira, MD, Juan-Manuel Sancho, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2584.
https://doi.org/10.1182/blood-2019-125683
Published: 2019
Journal Articles

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Pau Montesinos Fernandez, MD PhD, Christian Recher, MD PhD, Vadim Doronin, MD, Rodrigo T. Calado, MD PhD, Jun Ho Jang, MD PhD, Yasushi Miyazaki, MD PhD, Jianxiang Wang, MD, Diego A Gianolio, PhD, Scott R. Daigle, MS, Thomas Winkler, MD, Vickie Zhang, PhD, Peter Paschka, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2593.
https://doi.org/10.1182/blood-2019-123045
Published: 2019